LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-80
SponsorUniversity of Illinois at Chicago

About this trial

This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.

Eligibility criteria

Qualifiers

Age 50-80 years at the time of consent

USPSTF: ≥20 pack-years, currently smoke or quit ≤15 years ago.

Potter: 20 years of smoking, regardless of intensity

ACS: ≥20 pack-years, no restriction on quit time

Disqualifiers

Inability to undergo LDCT

Current diagnosis or history of lung cancer < 5 years prior to study enrollment.

Life expectancy <1 year

Active lung infection requiring systemic therapy

Trial design

Treatments tested in this trial

  • Sybil Artificial Intelligence (AI) screening

Treatment groups

2,500 Participants
are divided into 3 treatment groups